Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of YHD1119 in Subjects With Renal Impairment and Healthy Subjects
NCT05012436Phase 1Completed
- Sponsor
- Yuhan
- Start
- Jul 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of YHD1119 in neuropathic pain (2 arms), sponsored by Yuhan. Primary endpoints: Maximum Plasma Concentration at 72 hour and Area Under the Curve to Last Timepoint at 72 hour. Started Jul 2021; status: completed.
02
Drugs
YHD1119
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT05012436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05012436.